Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
01 août 2022 07h30 HE
|
Otonomy, Inc.
OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other...
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
25 juil. 2022 16h05 HE
|
Otonomy, Inc.
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line...
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
15 mars 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
28 févr. 2022 16h27 HE
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in...
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
22 févr. 2022 07h30 HE
|
Otonomy, Inc.
OTO-313 Phase 2 trial is fully enrolled ahead of scheduleTop-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a...
Otonomy Reports Corporate and Product Pipeline Update
06 janv. 2022 07h51 HE
|
Otonomy, Inc.
Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, Jan. 06, 2022 (GLOBE...
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
12 oct. 2021 07h30 HE
|
Otonomy, Inc.
Results published in Otology & Neurotology, a leading journal in fieldOTO-313 was well-tolerated and demonstrated a statistically significant higher proportion of responders than placebo across...
Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
05 avr. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
25 mars 2021 07h30 HE
|
Otonomy, Inc.
Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpointPatient enrollment criteria refined to enrich...
Otonomy to Participate in Three Upcoming Investor Conferences
25 févr. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...